VEGFA and central nervous system cancer: Thus, gliomas’ and GBMs’ antiangiogenic therapies aim to inhibit angiogenesis by using anti-VEGF monoclonal antibodies (mAbs) like bevacizumab or avoid VEGF binding to the receptor by blocking VEGFR2 with an mAb such as ramucirumab [93].